Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic LeukemiaJan A. Burger, Thomas J. Kipps, Alessandra Tedeschi et al.|New England Journal of Medicine|2015Cited by 1.6k
Ofatumumab As Single-Agent CD20 Immunotherapy in Fludarabine-Refractory Chronic Lymphocytic LeukemiaWilliam G. Wierda, Anders Österborg, Cathy Williams et al.|Journal of Clinical Oncology|2010Cited by 587
Alemtuzumab Compared With Chlorambucil As First-Line Therapy for Chronic Lymphocytic LeukemiaPeter Hillmen, Jiřı́ Mayer, Aleksander B. Skotnicki et al.|Journal of Clinical Oncology|2007Cited by 556
Zanubrutinib or Ibrutinib in Relapsed or Refractory Chronic Lymphocytic LeukemiaJennifer R. Brown, Mazyar Shadman, Barbara Eichhorst et al.|New England Journal of Medicine|2022Cited by 453
Assessment of imatinib as first-line treatment of chronic myeloid leukemia: 10-year survival results of the randomized CML study IV and impact of non-CML determinantsRoland J. Fuchs, Rüdiger Hehlmann, Michael Lauseker et al.|Leukemia|2017Cited by 339